MRC2

Across TCGA pan-cancer cohorts, MRC2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MRC2 data layer compared with 21 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MRC2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MRC2 expression acts as an unfavorable survival marker.

PDAC, LSCC, and UCEC are the cancer types where MRC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.254	0.607	.004	28	view →
LSCC	OS	Tertile	II,III,IV	0.741	1.000	.003	18	view →
UCEC	DFS	Quartile	II,III,IV	0.512	1.000	.025	8	view →
CCRCC	DFS	Median	All	0.576	0.850	.018	6	view →
LUAD	OS	Median	III,IV	0.750	0.997	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MRC2–PDAC (DFS)

Open the PDAC breakdown →